Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

A phase I-II dose ranging study of BMS-275183 (oral taxane) in combination with pemetrexed (Alimta) in patients with recurrent Non-Small Cell Lung Cancer (NSCLC). The safety and efficacy of this combination will be studied.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Taxane

Criteria

Inclusion Criteria:

• Advanced or metastatic pretreated NSCLC

• Measurable disease

• Adequate hematologic, hepatic and renal functions.

• ECOG Performance Status 0-2

Exclusion Criteria:

• Inability to swallow capsules

• Recent significant cardiovascular disease

• Women who are pregnant or breastfeeding